Browsing by Author "Kose, F."
Now showing 1 - 14 of 14
- Results Per Page
- Sort Options
Item Clinicohistopathological Features and Treatment Outcomes of Neuroendocrine Tumors; A Single Center Experience(2017) Sumbul, A. T.; Sedef, A. M.; Kose, F.; Mertsoylu, H.; Sezer, A.; Ozyilkan, O.; Abali, H.; https://orcid.org/0000-0002-5573-906X; https://orcid.org/0000-0001-8825-4918; D-4793-2014; AAD-2817-2021Item CONCURRENT CHEMORADIOTHERAPY WITH VINORELBINE PLUS SPLIT-DOSE CISPLATIN IN INOPERABLE STAGE III NON-SMALL CELL LUNG CANCER(2015) Mertsoylu, H.; Kose, F.; Sedef, A.M.; Dogan, O.; Parlak, C.; Besen, A.A.; Sumbul, A.T.; Findikcioglu, A.; Sezer, A.; Muallaoglu, S.Item Concurrent Chemoradiotherapy with Weekly Carboplatin-Paclitaxel May Be Feasible Option in Inoperable Stage III NSCLC(2017) Calikusu, Z.; Ugurluer, G.; Serin, M.; Sedef, A. M.; Mertsoylu, H.; Besen, A.; Kose, F.Item Cost Of Hepatocellular Carcinoma In Turkiye: Results Of A Delphi Panel Analysis(VALUE IN HEALTH, 2024-12) Dane, F.; Tatar, M.; Goker, E.; Yildiz, B.; Saglam, S.; Karaca, M.; Seker, M.; Sendur, M. A.; Dilber, F.; Lacin, S.; Dulundu, E.; Kose, F.; Aydogan, D.; Ozturk, B.; Yalcin, S.Item Diagnostic Accuracy Of Sentinel Node Biopsy In Non-Endometrioid, High-Grade And/Or Deep Myoinvasive Endometrial Cancer (Trsgo-Sln-006)(2021) Altin, D.; Taskin, S.; Tokgozoglu, N.; Vatansever, D.; Guler, A. H.; Gungor, M.; Tasci, T.; Bese, T.; Turan, H.; Kahramanoglu, I.; Yalcin, I.; Celik, C.; Demirkiran, F.; Kose, F.; Ortac, F. U.; Arvas, M.; Ayhan, A.; Taskiran, C.Item ENGOT-Ov65/KEYNOTE-B96: Phase III, Randomized, Double-Blind Study Of Pembrolizumab Vs Placebo Plus Paclitaxel With Optional Bevacizumab For Platinum-Resistant Recurrent Ovarian Cancer(2022) Colombo, N.; Coleman, R. L.; Wu, X.; Kose, F.; Wenham, R.; Sebastianelli, A.; Hasegawa, K.; Zsiros, E.; Rouge, T. De La Motte; Bidzinski, M.; McNeish, I.; Sehouli, J.; Korach, J.; Debruyne, P. R.; Kim, J-W.; De Melo, A. C.; Peng, X.; Bogusz, A. M.; Yamada, K.; Monk, B. J.Item The Hematologic Changes During Treatment In Cervical Cancer Patients Treated With Chemoradiotherapy(2018) Yildirim, B. Akkus; Onal, C.; Kose, F.; https://orcid.org/0000-0001-6661-4185; V-5717-2017; HOC-5611-2023Item The Impact of Sentinel Lymph Node Biopsy Alone on Survival of Patients with Endometrial Cancer (Trsgo-Sln-007)(2021) Alton, D.; Taskin, S.; Tokgozoglu, N.; (Vatansever, D.; Guler, A. H.; Gungor, M.; Tasci, T.; Turan, H.; Kahramanoglu, I.; Yalcin, I.; Celik, C.; Kose, F.; Ortac, F. U.; Arvas, M.; Ayhan, A.; Taskiran, C.Item Initial presentation of prostate cancer may hint different clinical characteristics along with serving predictive biomarker in castration-resistant prostate cancer patients treated with abiraterone acetate(2019) Kose, F.; Sedef, A.; Besen, A.; Mertsoylu, H.Item Multicenter real life expeMulticenter real life experience of biological agents in patients with metastatic colorectal cancerrience of biological agents in patients with metastatic colorectal cancer(2020) Demirci, U.; Erturk, I.; Arslan, C.; Bilici, A.; Cevik, D.; Cicin, I.; Dane, F.; Dolek, B.; Kaplan, M.; Karadurmus, N.; Kose, F.; Sendur, M.; Urun, Y.; Kilickap, S.Item Prediction of peritoneal recurrence in patients with gastric cancer: A multicenter study(2020) Kus, T.; Kose, F.; Aktas, G.; Yalcintas, U.; Sedef, A.; Cinkir, H.; Dirikoc, M.; Akkus, G.; Ozdemir, N.Item Predictive and prognostic role of T-regulatory cells in resected non-small cell lung cancer(2016) Kose, F.; Findikcioglu, A.; Canpolat, T.; Sedef, A.M.; Besen, A.; Mertsoylu, H.; Ozyilkan, O.; Abali, H.Item PROGNOSTIC ROLE OF T-REGULATORY CELLS IN COMPLETELY RESECTED EARLY STAGE NON-SMALL CELL LUNG CARCINOMA(2015) Kose, F.; Abali, H.; Findikcioglu, A.; Canpolat, T.; Besen, A.A.; Sumbul, A.T.; Mertsoylu, H.; Sedef, A.M.; Ozyilkan, O.Item The Role of Preoperative Routine Computed Tomography Scanning in The Estimation of High-Risk Factors in Endometrial Cancers(2018) Coban, G.; Erbay, G.; Kose, F.; Alemdaroglu, S.; Onal, C.; Celik, H.; https://orcid.org/0000-0002-3285-5519; https://orcid.org/0000-0002-1706-8680; https://orcid.org/0000-0002-0156-5973; https://orcid.org/0000-0003-4335-6659; https://orcid.org/0000-0002-2742-9021; AAI-9974-2021; AAK-5370-2021; G-4827-2016; AAI-8400-2021; HOC-5611-2023; AAL-1923-2021Objective: To examine the role of preoperative computed tomography (CT) in estimation of the high-risk factors in endometrial cancer cases. Materials and Methods: The data from 161 cases who were diagnosed with endometrioid adenocarcinoma with endometrial biopsy, and staged surgically were retrospectively analyzed. The diagnostic performance of a whole abdominal CT scan in terms of tumor diameter, myometrial invasion, cervical, adnexal, omental involvement, as well as pelvic para-aortic nodal involvement was examined. In addition, extra-uterine and extra-nodal incidental signs were identified. Results: The accuracy rate of preoperative CT scanning was found to be 42%, 78%, 80%, 95%, 97%, 88%, 89%, and 88% for tumor diameter, myometrial invasion, cervical, adnexal, and omental involvement, as well as pelvic para-aortic nodal involvement, respectively. Extra-uterine and extra-nodal incidental signs were identified in 18% of the cases. Incidental findings entailed a modification of management only in one case (0.62%). Conclusion: Preoperative CT scan findings do not present an alternative to intraoperative frozen section analysis or surgical staging. However, based on the findings from the preoperative CT scan, accuracy of predictions about which patients require more complex procedures (lymphadenectomy) can be improved, and therefore preoperative CT scanning may prove useful in more effective use of operating rooms.